Video

Davos 2019 - The Future of Healthcare w/ Ken Mulvany

Feb 4, 2019
HomeNEWSVideo
Davos 2019 - The Future of Healthcare w/ Ken Mulvany
Tagged:
Opinion

Live from Davos at the World Economic Forum, CNBC’s Elizabeth Schulze hosts a fireside chat with our Founder, Ken Mulvany, discussing how BenevolentAI is disrupting the pharma industry and exploring what the future of healthcare could look like.

In 2018 BenevolentAI was named a Technology Pioneer by the World Economic Forum and participated to the World Economic Forum Annual Meeting of the New Champions, held in Tianjin, China where we discussed how using AI can help unlock the world’s most complex operating system - the human body.

Receive our latest news
Featured Posts
News
BenevolentAI announces the appointment of biopharma luminary Dr François Nader as Chairman
News
Baricitinib, first identified by BenevolentAI as a COVID-19 treatment, is granted emergency use in India in response to its escalating crisis
Video
A New Era in Target Discovery: Collaborating with AstraZeneca on CKD and IPF
Follow us
More Posts

You Might Also Like

Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021
News
BenevolentAI announces the appointment of biopharma luminary Dr François Nader as Chairman
Dr Nader joins BenevolentAI as it embarks on ambitious growth plans to scale its AI platform, partnerships and drug portfolio.
Jul 9, 2021
Blog
Product design in AI-drug discovery: how to design products for and with scientific users
User interfaces can help drug discovery scientists to leverage insights from AI algorithms. Yet, designing products to enable scientific discovery is complex. Our product designer, Róża explores the key steps in her design process.
Jul 6, 2021
News
Baricitinib, first identified by BenevolentAI as a COVID-19 treatment, is granted emergency use in India in response to its escalating crisis
Baricitinib - first identified by BenevolentAI as a potential COVID-19 treatment - is accelerated for use in hospitalised patients in India following a continued surge in cases and fatalities.
May 5, 2021
Video
A New Era in Target Discovery: Collaborating with AstraZeneca on CKD and IPF
Finding the right target underpins the success of the entire drug discovery process. Learn how BenevolentAI’s collaboration with AstraZeneca is making a difference in CKD and IPF.
Apr 23, 2021
News
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population
Apr 8, 2021
Drug programmescareersCOVID-19Data Diversity initiative
Contact us →
Company Registration: 09781806
Terms & Conditions
Privacy & Cookies Policy